2. Academic Validation
  3. GD2-directed NAMPT inhibition using antibody-drug conjugates in neuroblastoma

GD2-directed NAMPT inhibition using antibody-drug conjugates in neuroblastoma

  • Eur J Med Chem. 2026 Apr 5:307:118691. doi: 10.1016/j.ejmech.2026.118691.
Jing Liu 1,  Qi Cheng 2,  Shangwei Huangfu 2,  Yueyang Zhang 3,  Biao Jiang 4,  Yinfeng Zhang 5,  Hongli Chen 6
Affiliations

Affiliations

  • 1 Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China; School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China; Shanghai Clinical Research and Trial Center, Shanghai, 201210, China.
  • 2 Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China; School of Physical Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
  • 3 Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
  • 4 Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China. Electronic address: jiangbiao@shanghaitech.edu.cn.
  • 5 Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China; Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. Electronic address: zhangyinfeng@scmc.com.cn.
  • 6 Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China. Electronic address: chenhl@shanghaitech.edu.cn.
PMID: 41707282 DOI: 10.1016/j.ejmech.2026.118691
Abstract

Inhibition of NAMPT to reprogram NAD+ metabolism and achieve antitumor activity has become an area of intense interest in Cancer metabolism. However, systemic NAMPT inhibition has been hampered by several toxicities due to the ubiquitous requirement of NAD+ in normal tissues. To overcome this limitation, we engineered A9, a GD2-directed antibody-drug conjugate that delivers a NAMPT Inhibitor selectively to a neuroblastoma model. A9 demonstrated potent, GD2-dependent cytotoxicity in GD2-high cells, while showing minimal cytotoxicity in GD2-low and normal cells. Mechanistically, A9 depletes intracellular NAD+ and ATP, triggering cell cycle arrest and Apoptosis. Co-administration of NMN, the direct product of NAMPT, fully restored ATP levels, prevented Apoptosis, and rescued cell viability, thereby confirming the on-target NAMPT inhibitory activity of the ADC. In vivo, A9 showed significant antitumor efficacy in SH-SY5Y xenograft model. Collectively, these findings establish A9 as a promising therapeutic approach for neuroblastoma, combing the metabolic vulnerability of NAMPT inhibition with the tumor selectivity of GD2-directed delivery to achieve potent and targeted antitumor activity.

Keywords

Antibody-drug conjugates; GD2-targeting; NAMPT inhibition; Neuroblastoma.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z